← Eichor
Study identifier: NCT06291714 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Non-invasive Measurement of the Hypotension Prediction Index for the Reduction of Intraoperative Hypotension

Condition: Intraoperative Hypotension · Acute Kidney Injury · Myocardial Injury After Non-cardiac Surgery  ·  Sponsor: University of Giessen

PhaseNA
Planned participants150
Who can joinAll sexes, 45 Years to no upper limit
Healthy volunteersNo

About this study

In order to reduce the incidence of IOH, various goal-directed therapy (GDT) protocols have already been introduced with success regarding the reduction of postoperative AKI and MINS. However, these studies used an invasive hemodynamic monitoring which offered a continuous surveillance of the blood pressure. In contrast, standard non-invasive blood pressure monitoring results in a blind gap between two measurements (mostly three or five minutes). In order to address this limitation, different continuous non-invasive blood pressure monitoring devices have been introduced. The next evolutional step of non-invasive cardiac output monitoring was to prevent IOH before their onset by using the Hypotension Prediction Index (HPI). Based on the Edward ́s monitoring platform, HPI is a monitoring tool which aims to predict IOH (defined as MAP\<65 mmHg for at least one minute) up to 15 min before its onset. The underlying machine learning based algorithm uses analyses features from the pressure waveform and was first calculated from a large retrospective data set of surgical patients and subsequently validated in a prospective cohort. In this study HPI showed a sensitivity of 88% and specificity of 87% for predicting IOH 15 min before its onset. Since then, own and studies of other working groups confirmed the effective prevention of IOH by the use of HPI-based GDT. Until today the arterial waveform analysis was dependent on invasive arterial measurement but since Edwards Lifesciences al…

This description comes directly from the study's public registry record.

Talk to the study team

Emmanuel Schneck, M.D.  ·  0049 641 985 44401  ·  emmanuel.schneck@chiru.med.uni-giessen.de

Michael Sander, Prof.  ·  0049 641 985 44401  ·  michael.sander@chiru.med.uni-giessen.de

Always discuss trial participation with your own doctor first.

Locations (1)

Justus-Liebig-University of GiessenGiessen, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06291714